Clicky

Crinetics Pharmaceuticals, Inc.(CRNX) News

Date Title
May 9 Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 8 Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 2 Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 11 Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 26 Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
Mar 22 Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
Mar 22 Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
Mar 21 Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Mar 21 Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
Mar 20 Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Mar 19 Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Mar 19 Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
Mar 19 UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study
Mar 19 Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Mar 12 Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Mar 11 Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 15 Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc
Feb 14 Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Feb 12 Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13 Crinetics Pharmaceuticals Inc Insider Sells Shares